Clinical implementation of pharmacogenetics: More than one gene at a time

Clinical Pharmacology and Therapeutics

Volumn 93, Issue 5, 2013, Pages 384-385

  Johnson, J A ^a   Klein, T E ^b   Relling, M V ^c  

^a UNIVERSITY OF FLORIDA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; TRICYCLIC ANTIDEPRESSANT AGENT; WARFARIN;

GENOTYPE; HUMAN; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP2D6; HUMANS;

EID: 84876529436     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2013.7     Document Type: Review

References (5)

1. Hicks, J.K. et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin. Pharmacol. Ther. 93, 402-408 (2013).
2. Johnson, J.A. et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 90, 625-629 (2011).
3. D'Andrea, G. et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood 105, 645-649 (2005).
4. Caldwell, M.D. et al. CYP4F2 genetic variant alters required warfarin dose. Blood 111, 4106-4112 (2008).
5. Takeuchi, F. et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 5, e1000433 (2009).